Mark M. Awad, MD, PhD, on Nivolumab Plus Ipilimumab in Resectable NSCLC: Recent Findings From CheckMate 816

Posted: Monday, April 29, 2024

Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses recent findings on neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer (NSCLC), including data on minimally invasive surgery, and the preventive or supportive interventions that might make neoadjuvant regimens more tolerable for patients.

---